Kuros Biosciences AG Company Description

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing.

The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG

Country	Switzerland
Founded	2016
Industry	Medical Devices
Sector	Healthcare
Employees	122
CEO	Christopher Fair

Contact Details

Address: Wagistrasse 25 Schlieren, 8952 Switzerland
Phone	41 44 733 4747
Website	kurosbio.com

Stock Details

Ticker Symbol	KURN
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0325814116
SIC Code	2836

Key Executives

Name	Position
Christopher T. Fair B.B.A.	Chief Executive Officer and Director
Daniel Geiger	Chief Financial Officer
Sjoerd Musters	Chief Operating Officer and GM of BV
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.	President of Innovation and Strategy and Executive Director
G. Joseph Ross	Senior Vice President of Marketing and Business Development
Laura Rosa	Senior Vice President of Global Human Resources
Dr. Philippe Saudan Ph.D.	Chief Development Officer
John Griffin	Chief Commercial Officer
Dr. Katherine Sage D.O., FAAOS, M.S.	Senior Vice President of Medical and Clinical Affairs
Dr. Virginia Jamieson	Consultant